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A Clinical Service to Support the Return
of Secondary Genomic Findings in Human Research
Andrew J. Darnell,1 Howard Austin,2 David A. Bluemke,3 Richard O. Cannon III,4 Kenneth Fischbeck,5
William Gahl,6 David Goldman,7 Christine Grady,8 Mark H. Greene,9 Steven M. Holland,10
Sara Chandros Hull,8,11 Forbes D. Porter,12 David Resnik,13 Wendy S. Rubinstein,14
and Leslie G. Biesecker15,*
Human genome and exome sequencing are powerful research tools that can generate secondary findings beyond the scope of the
research. Most secondary genomic findings are of low importance, but some (for a current estimate of 1%–3% of individuals) confer
high risk of a serious disease that could be mitigated by timely medical intervention. The impact and scope of secondary findings in
genome and exome sequencing will only increase in the future. There is considerable agreement that high-impact findings should be
returned to participants, but many researchers performing genomic research studies do not have the background, skills, or resources
to identify, verify, interpret, and return such variants. Here, we introduce a proposal for the formation of a secondary-genomic-findings
service (SGFS) that would support researchers by enabling the return of clinically actionable sequencing results to research participants
in a standardized manner. We describe a proposed structure for such a centralized service and evaluate the advantages and challenges of
the approach. We suggest that such a service would be of greater benefit to all parties involved than present practice, which is highly
variable. We encourage research centers to consider the adoption of a centralized SGFS.Introduction
Exome sequencing and genome se-
quencing (ES/GS) are increasingly
used in both clinical care and research
primarily because of their power to
identify the genetic etiology of dis-
ease.1–3 However, ES/GS also generate
secondaryfindings, previously referred
to as incidental findings. Hereinafter,
we adopt the terminology of the
Presidential Commission and use the
term ‘‘secondary.’’4 As defined by
the Commission, secondary genomic
findings are those findings that are
anticipated and can be actively
sought with a given procedure, such
as ES/GS, but are not the primary
target of the research evaluation.
Approaches to addressing the evalua-
tion and return of secondary genomic
findings in clinical practice have been
extensively discussed and debated.5–7
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been achieved in the realm of clinical
practice, approaches to secondary
genomic findings discovered in the
course of research studies are less
settled, and practices are highly vari-
able.4,8,9 This variation in practice in
the research community is problem-
atic for research participants and
leaves institutions, institutional re-
view boards (IRBs), and individual
research groups unclear about their
obligations toward participants. Re-
searchers and IRBs struggle with the
issue of secondary genomic findings
for many reasons, including debate
over the boundaries between clinical
care and research, concerns about
the role of participant preferences,
evaluation of risks and benefits to par-
ticipants, limited institutional re-
sources, and the lack of practical
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to research participants.10–12
A working group of NIH intramural
scientists assembled to address this
challenge. We first addressed two
sets of questions: (1) whether ES/GS
research studies should return second-
ary genomic findings and (2), if some
should be returned, what should
determine which research studies are
appropriate for the return of second-
ary genomic findings, which find-
ings warrant return, and how this
information should be disclosed. We
initially rejected two extreme options
in response to the first question:
(1) that all studies should return
results and (2) that none should do
so. We rejected option 1 because
mandating universal return of sec-
ondary genomic findings might be
inappropriate or highly impractical
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Figure 1. Graphical Representation of Some Key Attributes of Research Studies that
Argue For or Against Seeking and Returning Secondary Findingsrejected option 2 because not return-
ing research findings that might pro-
vide direct and easily derived benefits
for participants would violate the
principle of beneficence to research
participants, in at least some cases.
We therefore concluded that some
ES/GS research studies should return
some secondary genomic findings,
which then raised another set of ques-
tions related to which studies should
return secondary genomic findings,
which findings should be returned,
and how this should be accom-
plished. It is worth noting that we
also considered and rejected the
approach of deleting or masking data
(e.g., the sequences of genes that
could generate incidental findings).
We concluded that this was antithet-
ical to good genomic scientific prac-
tice, in that it potentially reduces the
chance of discovering primary find-
ings in genes that have pleiotropic
effects (e.g., variants that might cause
both dilated cardiomyopathy and
skeletal muscular dystrophy).
We suggest that the IRB, in collabo-
ration with the principal investigator
(PI) of the study, is the appropriate
body to determine which studies
should return secondary genomic
findings. The return of secondary436 The American Journal of Human Geneticsgenomic findings might not be appro-
priate for some research studies, even
if it is practical. This should be estab-
lished during the IRB review process.
Some of the factors that could be
considered include the timeliness,
quality or completeness of the
genomic analysis, relationship (or
the lack thereof) between the investi-
gator and research participant, poten-
tial importance to the subject (e.g., a
risk allele in a study of individuals
with a terminal illness), and others.
We have outlined some factors that
we believe to be germane to this deter-
mination in Figure 1. IRBs are well
positioned to critically and indepen-
dently analyze potential benefits and
harms to participants of returning sec-
ondary genomic findings, the attri-
butes of the study that favor or
disfavor return, and the available re-
sources for returning findings. The
IRB can also serve to educate and
inform researchers regarding their re-
sponsibilities and to standardize prac-
tice across research groups. By laying
the groundwork for the return of find-
ings whenever it is appropriate and
feasible, we also wish to build a pro-
cess that makes returning secondary
genomic findings more practical and
more common.98, 435–441, March 3, 2016Currently, there is a disconnect be-
tween what both researchers and
research participants say they prefer
with respect to secondary genomic
findings and what is actually occur-
ring, which is reflected in survey
data of relevant stakeholders. A mi-
nority of researchers (40%) reported
they were either already returning a
subset of secondary genomic findings
or planning to do so in the future. In
contrast, 95% of surveyed researchers
agreed that secondary genomic find-
ings should be returned to partici-
pants.8 A wide range of genetic
professionals hold the view that re-
turning some secondary genomic
findings from some types of studies
is appropriate.13–15 Furthermore, a
substantial majority of research par-
ticipants also consistently express
a strong interest in receiving at
least a subset of secondary genomic
findings.16–18 These data show a
gap between researchers’ desires and
preferences regarding the return of
secondary genomic findings and their
current practice and show that partic-
ipants generally expect the return
of secondary genomic findings. We
anticipate that creating the capability
to return secondary genomic findings
will alleviate a major concern about
validating findings and counseling
individuals about them and in turn
shift the decision-making process to-
ward favoring this approach. To
address these gaps in capability, we
propose a mechanism that will allow
researchers to fulfill their expressed
preference to return such results and
to meet the expectations of the partic-
ipants receiving secondary genomic
findings.
A Proposal for a Consultation
Service for Secondary Genomic
Research Findings
To address these issues, we propose a
secondary-genomic-findings service
(SGFS) as a mechanism for converting
ES/GS research data into analytically
valid secondary clinical findings and
providing medical and genetic coun-
seling for those findings. This service
would make available to PIs a service
that would take research-grade ES/GS
SGFS collates list of participants with 
negative findings analysis; presents non-
CLIA summary of findings to PI
IRB and PI agree to participate
Participants consented to analysis of data
PI performs primary sequencing
PI extracts variants from ES/GS data & 
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SGFS invites participant to
follow-up counseling and referral
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PI or SGFS enters medical order
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Figure 2. A Graphic Representation of the Steps Involved in the SGFS
Abbreviations are as follows: IRB, institutional review board; PI, principal investigator;
ES/GS, exome sequencing and genome sequencing; SGFS, secondary-genomic-findings
service; EHR, electronic health record; and CLIA, Clinical Laboratory Improvements
Amendment.data, screen it for pathogenic variants
from a specified gene list, resample
participants with such variants, vali-
date the variants in a clinically valid
manner, and return the variants to
the participants (Figure 2). The IRB
would consider the PI’s proposal for
handling secondary findings and
make a determination as to whether
the protocol and the participants
have attributes appropriate for the re-
turn of secondary findings (Figure 1).
If the answer is affirmative, the IRB
and PI would then work together to
implement appropriate informed con-
sent and a description of, including a
protocol for, the process. The servicewould provide four main functions
for researchers performing genome
or exome research: (1) identify poten-
tial clinically relevant secondary find-
ings from research data, (2) re-sample
research participants, (3) confirm any
secondary findings by clinical-grade
testing, and (4) provide medical and
genetic counseling for participants
when providing information about
findings.
In the case of a negative secondary-
findings analysis, i.e., one in which no
pathogenic results from the SGFS gene
list are identified, it is challenging to
address this issue while conforming
to the Clinical Laboratory Improve-The American Journal of Humanment Amendments (CLIA) regula-
tions that require communication of
only validated results (a negative sec-
ondary-findings analysis of research
data cannot practically be verified by
CLIA). We propose that the service
would provide the PI with a written
communication that the secondary-
findings analysis was performed ac-
cording to the then-current gene list
on a batch of ES/GS results and that
no variants meeting the standards
for reporting were found. It would be
the responsibility of the PI to commu-
nicate that message to the participant
by expressing only that there are no
such results to report, which is
distinct from saying that no variants
are present. This is critical because in
general, research ES/GS are not as sen-
sitive as clinical single-gene or gene-
panel testing. During the informed-
consent process, PIs or research staff
would need to explain to participants
in advance that a lack of confirmed
positive results does not necessarily
mean that no pathogenic variants
were present (in the scanned gene or
elsewhere in the genome) and that
the usual clinical indications for ge-
netic testing (e.g., a family history of
disease) still apply.
A key issue that needs to be ad-
dressed is the cost of such a service.
These include immediate costs (e.g.,
the cost of identifying, validating,
and communicating results to partici-
pants) and downstream costs (e.g.,
follow-up medical tests, genetic
testing, and medical care). We esti-
mate that the immediate costs would
include resources to support (1) the
time needed for the bioinformatician
and geneticist to screen the submitted
variants for the subset that is patho-
genic and clinically actionable, (2)
clinical re-sampling, (3) CLIA valida-
tion testing, and (3) the professional
time necessary for the return of re-
sults. The costs of the service can be
divided into those that are intrinsi-
cally part of the research enterprise
and those that are clinical services.
In the NIH Intramural Research Pro-
gram (IRP), all such costs must be
borne by the IRP itself, given that no
clinical costs are currently billed toGenetics 98, 435–441, March 3, 2016 437
third-party payers. We have estimated
these costs under varying assump-
tions of the number of exome or
genome sequences that are submitted
and analyzed and then amortized that
across all submitted sample files (that
is, we divide the cost across all submit-
ted sequences rather than charging
more for positive findings than for
negative findings.) These cost esti-
mates range from $26 to $83 per
exome (Supplemental Data). In the
extramural community, the costs of
the bioinformatician’s and geneticist’s
review of the research sequence data
would most likely not be billable as a
clinical service and would similarly
be borne by the institution as a
research infrastructure cost, presum-
ably supported by indirect funds or
institutional research resources.
It is more difficult to estimate the
downstream costs. The clinical ser-
vices, which comprise the majority
of the costs, could be billable as clin-
ical services. The PI and the IRB would
determine whether these clinical costs
would be billed to the participant or
insurer, charged to the researcher, or
funded by institutional resources. It
is difficult to estimate the potential
downstream clinical evaluation costs
with currently available data, but cur-
rent estimates19 suggest that it could
be cost effective (see below). This
question should be rigorously ad-
dressed in future studies.
We suggest that a SGFS should
begin with a goal of returning variants
from a relatively small list of genes for
disorders that have the highest poten-
tial medical impact, perhaps starting
with the list proposed by the Amer-
ican College of Medical Genetics and
Genomics for secondary findings
from clinical genomic testing5 or one
of those of other leading genomics
research programs.20 We believe there
is value in starting small and scaling
over time when implementing a
novel strategy in order to garner expe-
rience with respect to costs, benefits,
and potential harms of returning
such variants to research participants.
As discussed below, the ethical argu-
ments of beneficence and duty to
rescue are strongest for disorders that438 The American Journal of Human Geneticshave the greatest potential medical
benefit, which further justifies the ex-
penditures necessary for accomplish-
ing those research ethics goals. We
acknowledge that research partici-
pants might desire more information
than that included in the lists noted
above, but for the reasons articulated
below, we view that need as less
compelling in the early days of our
experience with this strategy.
Benefits Conferred by a SGFS
We suggest that implementing this
SGFS would have substantial practical
benefits. First and most importantly,
the service would provide a standard-
ized mechanism for potentially medi-
cally actionable genome or exome
results to be systematically returned
to research participants. Pathogenic
variants in the genes included in sec-
ondary-findings lists are associated
with severe or life-threatening disor-
ders that are commonly underdiag-
nosed and for which there are
effective medical interventions that
can potentially reduce morbidity or
mortality from the diseases or suscep-
tibilities associated with secondary
pathogenic variants.5 Second, partici-
pating researchers would benefit
from replacing what is now an arbi-
trary, ad hoc process with one that is
potentially more uniform and equi-
table to research participants. Investi-
gators would also be provided with a
mechanism for returning important
results, which they strongly endorse
but are not resourced to provide.
Third, uniformity in disclosure prac-
tices within an institution could avoid
potential negative perceptions of in-
stitutions as being unfair or arbitrary.
It is our hope that more research pro-
grams will be able to return secondary
findings when this service is estab-
lished.
Ethical Principles and the Return
of Secondary Findings
Various commentators and organi-
zations have identified numerous
ethical considerations related to re-
turning secondary findings in ES/GS;
these include beneficence, the duty
to rescue, respect for persons, justice,98, 435–441, March 3, 2016and non-maleficence.21–23 Although
each of these is relevant to decisions
about returning secondary genomic
findings, beneficence is the most
compelling and relevant principle.
This principle calls for maximizing
benefits and minimizing harms and
is one of the key principles underlying
ethical research, as explicated in the
Belmont Report.24 In this context,
identifying, validating, and commu-
nicating high-medical-impact vari-
ants from ES/GS research potentially
provide substantial clinical benefit
for participants. This benefit could
be realized at a reasonable cost19 and
at apparently low risk for the partici-
pants.25
The duty to rescue requires that in-
dividuals take reasonable measures to
help those who are in danger, such
as individuals with actionable genetic
variants that have clinical signifi-
cance. Researchers who discover
that an individual has such a variant
might be in a position to rescue that
individual from the danger posed
by the variant. Informing an individ-
ual about a dangerous variant discov-
ered during the course of research
is a reasonable measure that an
investigator can take to rescue that in-
dividual.21
Many participants would like to
learn about secondary findings, as
noted above. Consequently, returning
secondary genomic findings demon-
strates respect for the majority of
participants’ preferences and views.
Advising potential participants in the
informed-consent process that certain
secondary findings will be returned
also demonstrates respect for persons
and allows those who strongly object
to the receipt of secondary results to
decline research participation. Addi-
tionally, returning clinically impor-
tant findings demonstrates respect
by providing participants with infor-
mation they can use to make choices
concerning their health and life plans.
By extension, acting with respect and
recognizing the contributions of par-
ticipants will help to foster a stronger
relationship between investigators
and participants and promote trust.
Trust in the research enterprise is
becoming increasingly important as
the public realizes the potential utility
of ES/GS data and researchers include
more sequencing in their studies.
The principle of justice is also rele-
vant, because individuals in similar
situations should be treated similarly
and fairly. The service proposed here
can promote justice by ensuring equi-
table access to the possible benefits
of information about actionable sec-
ondary genomic findings. As noted
above, only a minority of researchers,
typically those with the available
resources to do so, are currently
providing secondary findings to par-
ticipants. In the absence of agreement
about any ethically relevant distinc-
tions among ES/GS research projects,
or among research participants, acting
in a way that allows more research
projects to deliver equally important
findings is an appropriate goal. Over-
all, it is desirable for the research en-
terprise to treat similar participants
similarly rather than arbitrarily with
regard to this benefit.
Potential Objections to the SGFS
and Challenges to Be Addressed
Although we are optimistic that this
proposal represents a net benefit to
participants and to the research enter-
prise, several possible drawbacks are
inherent within its structure and
merit further consideration. One ob-
jection might be that researchers
should allow participants more con-
trol over whether or not they receive
secondary genetic results. In our
proposal, participants would not
routinely receive findings in genes
outside of the pre-specified gene list
or those judged to not be clinically
important or actionable.26 However,
providing participants with informa-
tion during the consent process about
how secondary findings will be
handled allows them to make a deci-
sion about participating in the
research. If they do not agree with
how findings will be returned, they
can choose not to participate in
the study. Many sequencing results
will be of unknown significance, and
the decision to provide participants
only with clinically meaningful andactionable secondary findings from
ES/GS research is driven more by
beneficence than by autonomy.
Some would argue, in agreement
with clinical ES/GS recommenda-
tions,27 that participants might wish
to opt out of the secondary-findings
analysis. However, it is important to
recognize that opting out requires
extensive knowledge on the part of
the persons obtaining informed con-
sent so that participants understand
the potential significance of the infor-
mation they might be forgoing, such
as genetic information of potential
life-saving value to themselves or
their relatives. We propose that PIs
and IRBs will need to determine
whether this is appropriate for a given
protocol. There is also the question of
whether participants or investigators
might pick and choose among the
genes or disorders for which second-
ary-findings analysis could be per-
formed. We suggest that, with current
tools and resources, such customiza-
tion is impractical (although this
could change in the future). There-
fore, with a defined gene list that has
been vetted by institutional genetics
experts, professional organizations,
and an IRB available as a guide and
arbiter, we find it justifiable to restrict
research participants from choosing
which particular variants or genes
will be analyzed in their research
dataset.
Another possible issue related to
the proposed service is the potential
obligation to re-contact former partic-
ipants for updates on re-interpreta-
tions of variants detected long
after the initial analysis has been
completed. There has been discussion
concerning the extent of this obliga-
tion in the context of both research
and clinical care.28 Although we
acknowledge that re-contact could,
in some cases, provide a substantial
health benefit to research participants
whose data had been evaluated by the
service in the past, it is impractical to
revisit every past participant’s data
whenever the gene list or the interpre-
tation of variants is updated. At this
time, for practical reasons of cost and
logistics, we propose that this second-The American Journal of Humanary interpretation activity be per-
formed only once after the original
research ES/GS data are generated.
Further analyses would not be ex-
pected, although this issue should be
revisited as experience is gained and
in response to technologic advances.
It is important that the investigators’
intention to perform only a single
analysis to detect secondary findings
is clearly conveyed in the consent
process.
Finally, the risks of losing confiden-
tiality or privacy related to sharing
genomic data, which are often cited
as a concern in proposals to create in-
ter-institution databases of genomic-
variant information, must be carefully
managed with state-of-the art security
protections. Although there will
always be risks related to increased
handling, manipulation, transfer,
and reporting of genomic data, these
problems are not limited to the
context of a SGFS, and we expect
that the potential benefits of the ser-
vice will outweigh potential risks to
privacy and confidentiality.
Future Directions
We anticipate that the formation of
this service will benefit participants
by allowing them to receive informa-
tion about clinically meaningful and
actionable secondary genomic find-
ings and that it will benefit researchers
by addressing their obligations to par-
ticipants and clarifying what is
considered ethical conduct in the field
of clinical genomics research. We
believe that disclosure of meaningful
secondary genomic findings would
eventually become an expected
norm. We caution that this is only
an initial iteration of a solution to a
critical need in pursuit of what we
consider a worthwhile objective. A
number of issues, such as cost
management, unforeseen risks, partic-
ipant acceptance and understanding
of the limitations of the analyses
performed, and the result-disclosure
timeline associated with participa-
tion, will need to be studied and
evaluated once this service is imple-
mented. In addition, there is a theo-
retical concern that individuals mightGenetics 98, 435–441, March 3, 2016 439
engage in research studies in order to
undergo opportunistic screening for
secondary variants to address a need
for clinically indicated testing. We
fully expect that the SGFS would
evolve substantially in response to
research on these (and related) issues
in clinical genomics.
We recognize that this service
might further blur the gray area be-
tween the provision of clinical care
and the conduct of clinical research
because research protocols that use
this service might provide partici-
pants with significant clinical bene-
fits. Clearly distinguishing between
the goals of clinical care and those of
clinical research is thought to be
essential for protecting the rights of
patients and participants because it
helps them understand the purpose
of research and their potential to
benefit directly from participation.
We and others find the distinction
between clinical care and clinical
research to be increasingly strained
in ES/GS research because such
research simultaneously contributes
to the furthering of general knowl-
edge and the generation of individual
findings that might have clinical rele-
vance and utility. In other contexts,
such as learning healthcare sys-
tems,29 investigators have also begun
to recognize and acknowledge that
the ethics of research and clinical
care overlap more than has often
been recognized and that it might be
appropriate to work toward recon-
ciling and merging these activities in
some settings.30 Instead of trying
to convince participants that they
should not expect to benefit from
participating in research, investigators
should anticipate and accurately
communicate potential clinical bene-
fits in the consent process. At the
same time, we acknowledge that
many researchers are not yet (and
some might never be) equipped to
provide these clinical benefits in the
context of their research protocols,
given the fast pace at which genomic
sequencing technology has pro-
gressed. Accordingly, the SGFS pro-
posed here preserves the distinction
between research and clinical roles440 The American Journal of Human Geneticsby assigning responsibility for manag-
ing the clinically actionable aspects of
the endeavor to experienced clinical
genetics providers. This apportioning
of responsibility helps to more clearly
distinguish between the roles and in-
terests of the research team (i.e., dis-
covery of generalizable knowledge)
from those of the clinicians, whose re-
sponsibility it is to provide care in the
best interests of their patients.
A remaining challenge for the SGFS
is how to apply this approach to
research projects included in the sec-
ondary-findings service when the
participants lack the resources to
properly utilize its findings. For
example, a participant who is from a
resource-poor region where there are
no healthcare services accessible to
provide follow-up care might find it
difficult to use findings provided by
the SGFS. This situation presents a
difficult dilemma for PIs and IRBs.
On the one hand, it would seem to
be unfair to bar such a person from
participating in a study simply
because he or she might not be able
to access the resources needed to
benefit from clinically actionable re-
sults. On the other hand, it might be
inappropriate (and perhaps harmful)
to return results that a participant
cannot use or do something about.
The participant might experience
considerable worry and stress and
feel abandoned by the researchers.
We do not have a solution for this
problem, and we encourage further
discussion from relevant stakeholders.
In addition to the more immediate
potential benefits and challenges
described above, creation of a stan-
dardized process and service for the re-
turn of clinically actionable variants
to research participants would permit
research into the consequences of
the return of such secondary findings.
Because this SGFS would return a stan-
dardized set of variants in a consistent
manner to participants across a wide
spectrum of research projects, it can
serve as a source of empirical data for
evaluating the benefits or harms. We
encourage researchers to adopt sys-
tematic approaches to secondary find-
ings both for the benefit of individual98, 435–441, March 3, 2016participants and to facilitate improve-
ment in research practices overall.
This service, which we hope to imple-
ment in the multi-institute, multi-IRB
environment of the NIH IRP, could
serve as a template or model process
for similar services in extramural
institutions and will evolve as new
genomic discoveries come to light.Supplemental Data
Supplemental Data include two tables
and can be found with this article online
at http://dx.doi.org/10.1016/j.ajhg.2016.
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